Mark J. Gallardo
Research Subjects
Mark J. Gallardo has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
Anita Campbell
Grene Vision Group, Wichita, KS, USA
3 shared publicationsIqbal Ike K Ahmed
John A. Moran Eye Center, University of Utah, Salt Lake City, Utah; Prism Eye Institute, Toronto, Ontario; University of Toronto, Toronto, Ontario
3 shared publications- Jaime E Dickerson Jr
Sight Sciences, Inc., Menlo Park, CA, USA
3 shared publications - Kavita Dhamdhere
Sight Sciences, Inc., Menlo Park, CA, USA
3 shared publications Matthew Porter
School of Medicine Texas Tech University Health Sciences Center Lubbock TX USA
3 shared publicationsBrian E Flowers
Ophthalmology Associates, Fort Worth, TX, USA
2 shared publications
Latest Publications
- Open Access
- 9 September 2026
- Published by Elsevier in Ophthalmology Glaucoma
ELIOS Excimer Laser Trabeculostomy with Phacoemulsification in Primary Open-Angle Glaucoma
- 9 September 2026
- Published by Elsevier in Ophthalmology Glaucoma
Open AccessELIOS Excimer Laser Trabeculostomy with Phacoemulsification in Primary Open-Angle Glaucoma
- Open Access
- 1 March 2026
- Published by Wolters Kluwer Health in Journal of Cataract & Refractive Surgery
- Vol. 52 (3) , 310-311
Viscodilation of Schlemm canal and trabeculotomy for reducing intraocular pressure and medication use in pseudophakic eyes
- 1 March 2026
- Published by Wolters Kluwer Health in Journal of Cataract & Refractive Surgery
- Vol. 52 (3) , 310-311
Open AccessViscodilation of Schlemm canal and trabeculotomy for reducing intraocular pressure and medication use in pseudophakic eyes
- Open Access
- 1 February 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-13
Outcomes of Ab-Interno Canaloplasty and Gonioscopy-Assisted Transluminal Trabeculotomy in Eyes with Sustained Intraocular Pressure Elevation Following Intravitreal Injections
To evaluate the long-term efficacy and safety of combined ab-interno canaloplasty (ABiC) and gonioscopy-assisted transluminal trabeculotomy (GATT) with the iTrack microcatheter in patients with sustained intraocular pressure (IOP) elevation following intravitreal anti-VEGF or steroid injections. Patients and Methods: This was a retrospective, single-center study of patients who underwent ABiC and GATT with the iTrack microcatheter between 2017 and 2021 for secondary open-angle glaucoma or ocular hypertension following intravitreal injections. Eligible eyes had a preoperative IOP of ≥18 mmHg while on maximal tolerated medical therapy. Primary outcomes included IOP and glaucoma medication burden. Surgical success was defined using American Academy of Ophthalmology (AAO) criteria. Subgroup analyses were conducted by etiology (anti-VEGF vs steroid-induced). Kaplan-Meier analysis estimated cumulative success rates. Results: Thirty-four eyes from 30 patients were included, with a mean last follow-up of 15.3±9.8 months. Mean IOP was reduced by 46%, from 28.1±6.0 mmHg at baseline to 14.3±5.6 mmHg (p<0.001) at the last follow-up, while the number of medications decreased from 2.79±0.9 to 1.76±1.5 (p=0.001). Surgical success was achieved in 71% of eyes. Medication-free status was reached in 29% of eyes, compared with none at baseline, and 26% achieved IOP ≤15 mmHg without medications. Additional glaucoma procedures were needed in 11.8% of eyes. Combined ABiC and GATT remained effective in eyes receiving post-procedure intravitreal reinjections or prolonged topical steroid use. Kaplan-Meier analysis showed a survival probability above 70% at 25 months. Conclusion: Combined ab-interno canaloplasty and GATT using the iTrack microcatheter is a safe surgical option for selected eyes with sustained IOP elevation following intravitreal injections. The procedure achieved meaningful reductions in IOP and medication use, including in eyes requiring continued intravitreal therapy, supporting a primary surgical effect. Careful patient selection and longterm follow-up remain essential, as a subset of eyes may require additional intervention. Plain Language Summary: Some people who receive eye injections for conditions like macular degeneration or diabetic eye disease may develop higher eye pressure over time. This can lead to glaucoma, a condition that damages the optic nerve and can cause vision loss. Medicines to lower pressure do not always work well enough, and traditional glaucoma surgery can carry risks. We wanted to find out if ab-interno canaloplasty and gonioscopy-assisted transluminal trabeculotomy, combined together, could safely lower eye pressure in these patients. Both surgeries use a fine surgical thread, called a microcatheter, to open the natural drainage system of the eye and improve fluid outflow. We looked back at the medical records of 30 people (34 eyes) who had these combined procedures after developing high eye pressure following repeated injections or steroid treatment. At the latest follow-up visit, eye pressure had dropped by almost half and most people were able to reduce the number of daily eye drops they needed. About three out of four eyes met the standard definition of
- 1 February 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-13
Open AccessOutcomes of Ab-Interno Canaloplasty and Gonioscopy-Assisted Transluminal Trabeculotomy in Eyes with Sustained Intraocular Pressure Elevation Following Intravitreal Injections
To evaluate the long-term efficacy and safety of combined ab-interno canaloplasty (ABiC) and gonioscopy-assisted transluminal trabeculotomy (GATT) with the iTrack microcatheter in patients with sustained intraocular pressure (IOP) elevation following intravitreal anti-VEGF or steroid injections. Patients and Methods: This was a retrospective, single-center study of patients who underwent ABiC and GATT with the iTrack microcatheter between 2017 and 2021 for secondary open-angle glaucoma or ocular hypertension following intravitreal injections. Eligible eyes had a preoperative IOP of ≥18 mmHg while on maximal tolerated medical therapy. Primary outcomes included IOP and glaucoma medication burden. Surgical success was defined using American Academy of Ophthalmology (AAO) criteria. Subgroup analyses were conducted by etiology (anti-VEGF vs steroid-induced). Kaplan-Meier analysis estimated cumulative success rates. Results: Thirty-four eyes from 30 patients were included, with a mean last follow-up of 15.3±9.8 months. Mean IOP was reduced by 46%, from 28.1±6.0 mmHg at baseline to 14.3±5.6 mmHg (p<0.001) at the last follow-up, while the number of medications decreased from 2.79±0.9 to 1.76±1.5 (p=0.001). Surgical success was achieved in 71% of eyes. Medication-free status was reached in 29% of eyes, compared with none at baseline, and 26% achieved IOP ≤15 mmHg without medications. Additional glaucoma procedures were needed in 11.8% of eyes. Combined ABiC and GATT remained effective in eyes receiving post-procedure intravitreal reinjections or prolonged topical steroid use. Kaplan-Meier analysis showed a survival probability above 70% at 25 months. Conclusion: Combined ab-interno canaloplasty and GATT using the iTrack microcatheter is a safe surgical option for selected eyes with sustained IOP elevation following intravitreal injections. The procedure achieved meaningful reductions in IOP and medication use, including in eyes requiring continued intravitreal therapy, supporting a primary surgical effect. Careful patient selection and longterm follow-up remain essential, as a subset of eyes may require additional intervention. Plain Language Summary: Some people who receive eye injections for conditions like macular degeneration or diabetic eye disease may develop higher eye pressure over time. This can lead to glaucoma, a condition that damages the optic nerve and can cause vision loss. Medicines to lower pressure do not always work well enough, and traditional glaucoma surgery can carry risks. We wanted to find out if ab-interno canaloplasty and gonioscopy-assisted transluminal trabeculotomy, combined together, could safely lower eye pressure in these patients. Both surgeries use a fine surgical thread, called a microcatheter, to open the natural drainage system of the eye and improve fluid outflow. We looked back at the medical records of 30 people (34 eyes) who had these combined procedures after developing high eye pressure following repeated injections or steroid treatment. At the latest follow-up visit, eye pressure had dropped by almost half and most people were able to reduce the number of daily eye drops they needed. About three out of four eyes met the standard definition of
- Open Access
- 1 February 2025
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 19, 469-481
Efficacy and Safety of Cataract Surgery Combined with Ab Interno Canaloplasty and Micro-Trabecular Bypass Stent Surgery in Open-Angle Glaucoma
Purpose: To evaluate the effectiveness of canaloplasty via an ab-interno technique using the iTrack (Nova Eye Medical, Fremont, USA) combined with microtrabecular bypass stent surgery with the Hydrus microstent (Ivantis, Inc, Irvine, CA) following cataract surgery (CE) in patients with primary open-angle glaucoma (POAG). Methods: A retrospective, two-center, case series of 51 POAG eyes that underwent phacoemulsification followed by canaloplasty combined with microtrabecular bypass stent surgery. Eyes were categorized according to IOP and disease severity. A subgroup of patients on 3+ medications at baseline was included. Primary end points included the mean IOP and mean number of medications at 12 months, 24 months and at the last follow-up. Results: Baseline IOP (mmHg) and number of medications were 19.1± 4.0 and 2.3± 1.2 and reduced to 13.9± 2.6 (p< 0.001) and 1.2± 1.4 (p< 0.001) at 12 months, 13.7± 2.0 and 1.5± 1.5 (p< 0.001, p=0.008, respectively) at 24 months (n=31) and 14.4± 3.2 and 2.1± 1.5 (p< 0.001, p=0.5, respectively) at 36 months. In the uncontrolled group (n=27), baseline IOP and number of medications were 21.9± 3.1 and 1.9± 1.3 and reduced to 14.6± 4.2 (p=0.006) and 1.7± 1.6 (p=0.821) at 36 months postoperatively. Baseline IOP and number of medications of severe patients (n=12) were 19.0± 4.8 and 1.9± 1.1. IOP reduced to 12.8± 2.4 (p=0.005) at 12 months while the number of medications did not show any statistically significant change: 1.9± 1.6 (p=0.4). No eyes underwent additional glaucoma surgery in the study period. Conclusion: Canaloplasty combined with microtrabecular bypass stent surgery following cataract extraction demonstrated efficacy in reducing IOP and medication burden up to 24 months postoperatively. IOP reduction was also sustained up to 36 months postoperatively. The combined MIGS procedure is also effective in eyes with uncontrolled glaucoma.
- 1 February 2025
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 19, 469-481
Open AccessEfficacy and Safety of Cataract Surgery Combined with Ab Interno Canaloplasty and Micro-Trabecular Bypass Stent Surgery in Open-Angle Glaucoma
Purpose: To evaluate the effectiveness of canaloplasty via an ab-interno technique using the iTrack (Nova Eye Medical, Fremont, USA) combined with microtrabecular bypass stent surgery with the Hydrus microstent (Ivantis, Inc, Irvine, CA) following cataract surgery (CE) in patients with primary open-angle glaucoma (POAG). Methods: A retrospective, two-center, case series of 51 POAG eyes that underwent phacoemulsification followed by canaloplasty combined with microtrabecular bypass stent surgery. Eyes were categorized according to IOP and disease severity. A subgroup of patients on 3+ medications at baseline was included. Primary end points included the mean IOP and mean number of medications at 12 months, 24 months and at the last follow-up. Results: Baseline IOP (mmHg) and number of medications were 19.1± 4.0 and 2.3± 1.2 and reduced to 13.9± 2.6 (p< 0.001) and 1.2± 1.4 (p< 0.001) at 12 months, 13.7± 2.0 and 1.5± 1.5 (p< 0.001, p=0.008, respectively) at 24 months (n=31) and 14.4± 3.2 and 2.1± 1.5 (p< 0.001, p=0.5, respectively) at 36 months. In the uncontrolled group (n=27), baseline IOP and number of medications were 21.9± 3.1 and 1.9± 1.3 and reduced to 14.6± 4.2 (p=0.006) and 1.7± 1.6 (p=0.821) at 36 months postoperatively. Baseline IOP and number of medications of severe patients (n=12) were 19.0± 4.8 and 1.9± 1.1. IOP reduced to 12.8± 2.4 (p=0.005) at 12 months while the number of medications did not show any statistically significant change: 1.9± 1.6 (p=0.4). No eyes underwent additional glaucoma surgery in the study period. Conclusion: Canaloplasty combined with microtrabecular bypass stent surgery following cataract extraction demonstrated efficacy in reducing IOP and medication burden up to 24 months postoperatively. IOP reduction was also sustained up to 36 months postoperatively. The combined MIGS procedure is also effective in eyes with uncontrolled glaucoma.
- Open Access
- 1 July 2024
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 18, 1971-1980
Incidence of Postsurgical Intraocular Inflammation 6 Months After Implantation with a Multifocal Intraocular Lens
Purpose: This study assessed the incidence of postsurgical intraocular inflammation after cataract extraction by phacoemulsification and implantation with AcrySof IQ ReSTOR intraocular lenses (IOLs) produced using an updated manufacturing process. Incidence rates were compared with historical rates of postsurgical intraocular inflammation. Methods: This was a prospective, multicenter, post-approval study at 34 sites. Patients aged ≥ 22 years received a study lens in at least 1 eye. Postsurgical intraocular inflammation (aqueous cell grade ≥ 3+ within 14 days after surgery, aqueous cell ≥ 2+ at 14 to ≤ 60 days after surgery, or aqueous cell ≥ 1+ at > 60 days) was assessed within a 180-day period after implantation. Rates of toxic anterior segment syndrome (TASS), acute postoperative endophthalmitis, chronic postoperative endophthalmitis, and uncategorized cases of postsurgical intraocular inflammation were assessed. Ocular adverse events (AEs) and ocular adverse device effects (ADEs) were evaluated. Historical rates of postsurgical intraocular inflammation were determined from the 2011– 2013 Medicare Limited Data Set files (a 5% sample of the Medicare data set representative of patients aged ≥ 65 years). Results: Final safety analysis set included 3357 eyes (1792 patients; mean age, 68.6 ± 7.9 years). Postsurgical intraocular inflammation (any type) rate was 5.1 per 1000 attempted IOL implants (95% CI, 2.95, 8.10). TASS, acute postoperative endophthalmitis, and uncategorized inflammation rates were 0.6 (95% CI, 0.07, 2.15), 0.3 (95% CI, 0.01, 1.66), and 4.2 (95% CI, 2.28, 6.99) per 1000 attempted IOL implants, respectively. There were no events of chronic postoperative endophthalmitis. Ocular AEs and ADEs were reported in 17% and 1.5% of eyes, respectively. Most common ADEs were halo (0.63%) and glare (0.51%). The historical postsurgical inflammation rate from 221,519 cataract procedures was 10.3/1000 cataract surgeries, and the endophthalmitis rate was 1.2/1000 surgeries. Conclusion: The updated IOL manufacturing process resulted in postoperative intraocular inflammation rates that were substantially lower than the historic rate.
- 1 July 2024
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 18, 1971-1980
Open AccessIncidence of Postsurgical Intraocular Inflammation 6 Months After Implantation with a Multifocal Intraocular Lens
Purpose: This study assessed the incidence of postsurgical intraocular inflammation after cataract extraction by phacoemulsification and implantation with AcrySof IQ ReSTOR intraocular lenses (IOLs) produced using an updated manufacturing process. Incidence rates were compared with historical rates of postsurgical intraocular inflammation. Methods: This was a prospective, multicenter, post-approval study at 34 sites. Patients aged ≥ 22 years received a study lens in at least 1 eye. Postsurgical intraocular inflammation (aqueous cell grade ≥ 3+ within 14 days after surgery, aqueous cell ≥ 2+ at 14 to ≤ 60 days after surgery, or aqueous cell ≥ 1+ at > 60 days) was assessed within a 180-day period after implantation. Rates of toxic anterior segment syndrome (TASS), acute postoperative endophthalmitis, chronic postoperative endophthalmitis, and uncategorized cases of postsurgical intraocular inflammation were assessed. Ocular adverse events (AEs) and ocular adverse device effects (ADEs) were evaluated. Historical rates of postsurgical intraocular inflammation were determined from the 2011– 2013 Medicare Limited Data Set files (a 5% sample of the Medicare data set representative of patients aged ≥ 65 years). Results: Final safety analysis set included 3357 eyes (1792 patients; mean age, 68.6 ± 7.9 years). Postsurgical intraocular inflammation (any type) rate was 5.1 per 1000 attempted IOL implants (95% CI, 2.95, 8.10). TASS, acute postoperative endophthalmitis, and uncategorized inflammation rates were 0.6 (95% CI, 0.07, 2.15), 0.3 (95% CI, 0.01, 1.66), and 4.2 (95% CI, 2.28, 6.99) per 1000 attempted IOL implants, respectively. There were no events of chronic postoperative endophthalmitis. Ocular AEs and ADEs were reported in 17% and 1.5% of eyes, respectively. Most common ADEs were halo (0.63%) and glare (0.51%). The historical postsurgical inflammation rate from 221,519 cataract procedures was 10.3/1000 cataract surgeries, and the endophthalmitis rate was 1.2/1000 surgeries. Conclusion: The updated IOL manufacturing process resulted in postoperative intraocular inflammation rates that were substantially lower than the historic rate.
- Open Access
- 1 January 2024
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 18, 173-183
Consistency in Standalone Canaloplasty Outcomes Using the iTrack Microcatheter
Purpose: To study the consistency in outcomes of standalone canaloplasty performed via an ab-interno surgical technique in reducing intraocular pressure (IOP) and number of medications in uncontrolled open-angle glaucoma (OAG) eyes over a 12-month period. Methods: This retrospective multicenter case series included patients who underwent standalone canaloplasty via an ab-interno surgical technique using the iTrack microcatheter (Nova Eye, Inc., Fremont, USA) and had preoperative uncontrolled OAG (IOP≥ 18mmHg) along with no previous glaucoma surgery. The iTrack microcatheter is used to circumnavigate 360° and viscodilate Schlemm’s canal. Consistency of IOP and medications reduction on an eye-by-eye basis were evaluated to understand the outcomes in each single eye. Results: Sixty-four eyes of 60 patients (age 71.5± 13.4 years) were included. Six eyes (9%) that underwent additional glaucoma surgery were considered a failure and were subsequently excluded from analysis. At 12 months, IOP was reduced in 57 of the 58 (89%) remaining eyes; one eye had the same IOP with a reduced number of medications. Of the 57/58 eyes with a reduced IOP: 44 eyes (69%) required fewer medications; 12 eyes (19%) required the same number of medications. Of these 58 eyes, 78% of eyes had a ≥ 20% reduction in IOP compared to baseline; 69% eyes had a postoperative IOP ≤ 15 mmHg, and 86% eyes ≤ 18 mmHg at 12 months. Forty percent of the eyes were medication-free at 12 months compared to none at baseline. Conclusion: Canaloplasty performed via an ab-interno surgical technique as a standalone procedure consistently reduced IOP and glaucoma medications in almost all eyes.
- 1 January 2024
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 18, 173-183
Open AccessConsistency in Standalone Canaloplasty Outcomes Using the iTrack Microcatheter
Purpose: To study the consistency in outcomes of standalone canaloplasty performed via an ab-interno surgical technique in reducing intraocular pressure (IOP) and number of medications in uncontrolled open-angle glaucoma (OAG) eyes over a 12-month period. Methods: This retrospective multicenter case series included patients who underwent standalone canaloplasty via an ab-interno surgical technique using the iTrack microcatheter (Nova Eye, Inc., Fremont, USA) and had preoperative uncontrolled OAG (IOP≥ 18mmHg) along with no previous glaucoma surgery. The iTrack microcatheter is used to circumnavigate 360° and viscodilate Schlemm’s canal. Consistency of IOP and medications reduction on an eye-by-eye basis were evaluated to understand the outcomes in each single eye. Results: Sixty-four eyes of 60 patients (age 71.5± 13.4 years) were included. Six eyes (9%) that underwent additional glaucoma surgery were considered a failure and were subsequently excluded from analysis. At 12 months, IOP was reduced in 57 of the 58 (89%) remaining eyes; one eye had the same IOP with a reduced number of medications. Of the 57/58 eyes with a reduced IOP: 44 eyes (69%) required fewer medications; 12 eyes (19%) required the same number of medications. Of these 58 eyes, 78% of eyes had a ≥ 20% reduction in IOP compared to baseline; 69% eyes had a postoperative IOP ≤ 15 mmHg, and 86% eyes ≤ 18 mmHg at 12 months. Forty percent of the eyes were medication-free at 12 months compared to none at baseline. Conclusion: Canaloplasty performed via an ab-interno surgical technique as a standalone procedure consistently reduced IOP and glaucoma medications in almost all eyes.
- Open Access
- 13 May 2023
- Published by Springer Nature in Ophthalmology and Therapy
- Vol. 12 (4) , 1973-1987
Efficacy and Safety of Pairing iStent Inject Trabecular Micro-Bypass and iAccess Precision Blade Goniotomy in Patients with Open-Angle Glaucoma
Introduction This study evaluated efficacy and safety of implanting two second-generation trabecular micro-bypass stents (iStent inject/iStent inject W) with phacoemulsification, either with or without iAccess Precision Blade goniotomy, in patients with mild-to-moderate open-angle glaucoma (OAG). Methods This retrospective, non-randomized, unmasked, dual-arm, single-site, multi-surgeon, consecutive case series evaluated all OAG eyes that underwent phacoemulsification and iStent inject implantation either as a dual procedure (group A) or paired with iAccess goniotomy (group B) from July 2020 to May 2022. Effectiveness outcomes analyzed from 1 month onward included intraocular pressure (IOP), proportions of eyes with IOP ≤ 12/≤ 15/≤ 18, proportion medication-free, and medication number. Safety outcomes at all timepoints included adverse events and secondary surgeries. Results In group A, mean IOP reduced from 14.9 ± 3.2 mmHg on 1.22 ± 1.31 mean medications preoperatively (n = 63) to 13.5 ± 2.5 mmHg on 0.24 ± 0.61 medications at month 3 (n = 34; p = 0.048 IOP, p < 0.001 medications). In group B, mean IOP reduced from 16.0 ± 4.2 mmHg on 1.12 ± 1.07 medications preoperatively (n = 93) to 12.2 ± 2.3 mmHg on 0.57 ± 1.27 medications at month 3 (n = 23; p < 0.001 IOP, p = 0.003 medications). From preoperative to 3 months, the percent of eyes with IOP ≤ 12 mmHg remained at 32.4% in group A (p = 1.0) and rose from 21.7% to 60.9% in group B (p = 0.0177); eyes with IOP ≤ 15 mmHg rose from 52.9% to 76.5% in group A (p = 0.0963) and from 43.5% to 91.3% in group B (p = 0.0034). Adjusting for baseline between-group differences, group B had significantly greater postoperative IOP reduction than group A (p = 0.043); medication reductions were similar. Safety was favorable in both groups. Conclusions Phacoemulsification and iStent inject with or without iAccess Precision Blade goniotomy produced clinically meaningful and safe IOP and medication reductions. The paired iStent inject + iAccess + phacoemulsification procedure enabled greater IOP reduction and lower IOP thresholds than iStent inject + phacoemulsification. The study provides some of the first data on this paired approach and on the novel iAccess Precision Blade.
- 13 May 2023
- Published by Springer Nature in Ophthalmology and Therapy
- Vol. 12 (4) , 1973-1987
Open AccessEfficacy and Safety of Pairing iStent Inject Trabecular Micro-Bypass and iAccess Precision Blade Goniotomy in Patients with Open-Angle Glaucoma
Introduction This study evaluated efficacy and safety of implanting two second-generation trabecular micro-bypass stents (iStent inject/iStent inject W) with phacoemulsification, either with or without iAccess Precision Blade goniotomy, in patients with mild-to-moderate open-angle glaucoma (OAG). Methods This retrospective, non-randomized, unmasked, dual-arm, single-site, multi-surgeon, consecutive case series evaluated all OAG eyes that underwent phacoemulsification and iStent inject implantation either as a dual procedure (group A) or paired with iAccess goniotomy (group B) from July 2020 to May 2022. Effectiveness outcomes analyzed from 1 month onward included intraocular pressure (IOP), proportions of eyes with IOP ≤ 12/≤ 15/≤ 18, proportion medication-free, and medication number. Safety outcomes at all timepoints included adverse events and secondary surgeries. Results In group A, mean IOP reduced from 14.9 ± 3.2 mmHg on 1.22 ± 1.31 mean medications preoperatively (n = 63) to 13.5 ± 2.5 mmHg on 0.24 ± 0.61 medications at month 3 (n = 34; p = 0.048 IOP, p < 0.001 medications). In group B, mean IOP reduced from 16.0 ± 4.2 mmHg on 1.12 ± 1.07 medications preoperatively (n = 93) to 12.2 ± 2.3 mmHg on 0.57 ± 1.27 medications at month 3 (n = 23; p < 0.001 IOP, p = 0.003 medications). From preoperative to 3 months, the percent of eyes with IOP ≤ 12 mmHg remained at 32.4% in group A (p = 1.0) and rose from 21.7% to 60.9% in group B (p = 0.0177); eyes with IOP ≤ 15 mmHg rose from 52.9% to 76.5% in group A (p = 0.0963) and from 43.5% to 91.3% in group B (p = 0.0034). Adjusting for baseline between-group differences, group B had significantly greater postoperative IOP reduction than group A (p = 0.043); medication reductions were similar. Safety was favorable in both groups. Conclusions Phacoemulsification and iStent inject with or without iAccess Precision Blade goniotomy produced clinically meaningful and safe IOP and medication reductions. The paired iStent inject + iAccess + phacoemulsification procedure enabled greater IOP reduction and lower IOP thresholds than iStent inject + phacoemulsification. The study provides some of the first data on this paired approach and on the novel iAccess Precision Blade.
- Open Access
- 25 March 2023
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 252, 306-325
Gel Stent Versus Trabeculectomy: The Randomized, Multicenter, Gold-Standard Pathway Study (GPS) of Effectiveness and Safety at 12 Months
- 25 March 2023
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 252, 306-325
Open AccessGel Stent Versus Trabeculectomy: The Randomized, Multicenter, Gold-Standard Pathway Study (GPS) of Effectiveness and Safety at 12 Months
- Open Access
- 20 October 2022
- Published by Wolters Kluwer Health in Journal of Glaucoma
- Vol. 32 (1) , 9-18
Effectiveness and Safety of iStent Infinite Trabecular Micro-Bypass for Uncontrolled Glaucoma
Précis:Purpose: Evaluate safety and effectiveness of the iStent infinite Trabecular Micro-Bypass System in patients with open-angle glaucoma (OAG) uncontrolled by prior surgical or medical therapy. Design: Prospective, multicenter, single-arm, open-label clinical trial. Methods: Implantation of iStent infinite (3 iStent inject W stents) was performed as a standalone surgical procedure in eyes with OAG uncontrolled by prior incisional or cilioablative surgeries or maximally-tolerated medical therapy (MTMT). Prospectively-declared effectiveness endpoints were proportion of eyes achieving ≥20% mean diurnal intraocular pressure (MDIOP) reduction from Baseline at Month 12 on the same or fewer IOP-lowering medication classes (responder endpoint) and mean change in MDIOP from Baseline at Month 12. Safety parameters included visual acuity, slit-lamp and fundus examinations, gonioscopy, perimetry, surgical complications, and adverse events. Results: Seventy-two eyes of 72 patients (mean age 71.9 y) with preoperative mean medicated MDIOP of 23.4±2.8 mmHg on a mean of 3.1±0.9 IOP-lowering medication classes were enrolled: 61 eyes with failed prior surgery/ies (Failed-Surgery subgroup) and 11 eyes uncontrolled on MTMT (MTMT subgroup). 76.1% of all enrolled patients met the responder endpoint (73.4% Failed-Surgery, 90.9% MTMT), with mean reduction (SE) in MDIOP at Month 12 of 5.9(0.6) mmHg (5.5(0.7) mmHg Failed-Surgery subgroup, 8.1(0.9) mmHg MTMT subgroup). For patients on the same or fewer medication as Baseline, 53.0% achieved ≥30% MDIOP reduction without surgical interventions/other events. Safety was favorable, with no explants, infection, or device-related interventions or hypotony. Conclusions: iStent infinite standalone surgery achieved clinically significant IOP reduction and favorable safety in patients with OAG uncontrolled by prior therapy.
- 20 October 2022
- Published by Wolters Kluwer Health in Journal of Glaucoma
- Vol. 32 (1) , 9-18
Open AccessEffectiveness and Safety of iStent Infinite Trabecular Micro-Bypass for Uncontrolled Glaucoma
Précis:Purpose: Evaluate safety and effectiveness of the iStent infinite Trabecular Micro-Bypass System in patients with open-angle glaucoma (OAG) uncontrolled by prior surgical or medical therapy. Design: Prospective, multicenter, single-arm, open-label clinical trial. Methods: Implantation of iStent infinite (3 iStent inject W stents) was performed as a standalone surgical procedure in eyes with OAG uncontrolled by prior incisional or cilioablative surgeries or maximally-tolerated medical therapy (MTMT). Prospectively-declared effectiveness endpoints were proportion of eyes achieving ≥20% mean diurnal intraocular pressure (MDIOP) reduction from Baseline at Month 12 on the same or fewer IOP-lowering medication classes (responder endpoint) and mean change in MDIOP from Baseline at Month 12. Safety parameters included visual acuity, slit-lamp and fundus examinations, gonioscopy, perimetry, surgical complications, and adverse events. Results: Seventy-two eyes of 72 patients (mean age 71.9 y) with preoperative mean medicated MDIOP of 23.4±2.8 mmHg on a mean of 3.1±0.9 IOP-lowering medication classes were enrolled: 61 eyes with failed prior surgery/ies (Failed-Surgery subgroup) and 11 eyes uncontrolled on MTMT (MTMT subgroup). 76.1% of all enrolled patients met the responder endpoint (73.4% Failed-Surgery, 90.9% MTMT), with mean reduction (SE) in MDIOP at Month 12 of 5.9(0.6) mmHg (5.5(0.7) mmHg Failed-Surgery subgroup, 8.1(0.9) mmHg MTMT subgroup). For patients on the same or fewer medication as Baseline, 53.0% achieved ≥30% MDIOP reduction without surgical interventions/other events. Safety was favorable, with no explants, infection, or device-related interventions or hypotony. Conclusions: iStent infinite standalone surgery achieved clinically significant IOP reduction and favorable safety in patients with OAG uncontrolled by prior therapy.
- Open Access
- 1 July 2022
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 16, 2187-2197
Comparison of Clinical Outcomes Following Gel Stent Implantation via Ab-Externo and Ab-Interno Approaches in Patients with Refractory Glaucoma
Purpose: To compare clinical outcomes following gel stent implantation via ab externo and ab interno approaches in patients with refractory glaucoma. Patients and Methods: This retrospective study included 203 eyes of 185 patients aged ≥ 45 years who underwent Xen gel stent implantation as a standalone procedure for medically uncontrolled glaucoma (intraocular pressure (IOP) ≥ 18 mmHg) despite maximum tolerable IOP-lowering medications. One hundred and five eyes underwent gel stent implantation via ab interno approach and 98 via ab externo. Patients with prior conjunctival-incisional glaucoma or cataract surgery were also included. Study parameters were reduction in IOP and number of IOP-lowering medications from baseline to 3, 6, 9 and 12 months postoperatively. Results: There were no statistically significant differences in the age, sex, preoperative IOP, number of IOP-lowering medications or cup–disc ratio between the ab interno and ab externo groups at baseline (p > 0.05). At all postoperative time points, mean IOP and percentage reduction from baseline were comparable in both groups (p > 0.05) except at postoperative 6 months when the outcomes were significantly better (p < 0.05) in the ab externo group. The rate of postoperative procedures (5-Fluorouracil injections and bleb needling), the incidence of numerical or clinical hypotony and adverse events were comparable in both groups (p > 0.05). The mean number of IOP-lowering medications was comparable in both groups at all time points. Conclusion: The Xen gel stent, whether implanted ab interno or ab externo, is effective in reducing IOP and dependence on topical medications in eyes with refractory glaucoma. The stent may be used in both phakic and pseudophakic patients and is a reasonable option for patients with prior failed trabeculectomy.
- 1 July 2022
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 16, 2187-2197
Open AccessComparison of Clinical Outcomes Following Gel Stent Implantation via Ab-Externo and Ab-Interno Approaches in Patients with Refractory Glaucoma
Purpose: To compare clinical outcomes following gel stent implantation via ab externo and ab interno approaches in patients with refractory glaucoma. Patients and Methods: This retrospective study included 203 eyes of 185 patients aged ≥ 45 years who underwent Xen gel stent implantation as a standalone procedure for medically uncontrolled glaucoma (intraocular pressure (IOP) ≥ 18 mmHg) despite maximum tolerable IOP-lowering medications. One hundred and five eyes underwent gel stent implantation via ab interno approach and 98 via ab externo. Patients with prior conjunctival-incisional glaucoma or cataract surgery were also included. Study parameters were reduction in IOP and number of IOP-lowering medications from baseline to 3, 6, 9 and 12 months postoperatively. Results: There were no statistically significant differences in the age, sex, preoperative IOP, number of IOP-lowering medications or cup–disc ratio between the ab interno and ab externo groups at baseline (p > 0.05). At all postoperative time points, mean IOP and percentage reduction from baseline were comparable in both groups (p > 0.05) except at postoperative 6 months when the outcomes were significantly better (p < 0.05) in the ab externo group. The rate of postoperative procedures (5-Fluorouracil injections and bleb needling), the incidence of numerical or clinical hypotony and adverse events were comparable in both groups (p > 0.05). The mean number of IOP-lowering medications was comparable in both groups at all time points. Conclusion: The Xen gel stent, whether implanted ab interno or ab externo, is effective in reducing IOP and dependence on topical medications in eyes with refractory glaucoma. The stent may be used in both phakic and pseudophakic patients and is a reasonable option for patients with prior failed trabeculectomy.